Jami rubin goldman sachs biography samples

CHICAGO — Detection Venture Partners today announced the nomination of life sciences industry veteran Jami Rubin as Venture Partner.

“ARCH is enduring to building an extraordinary team provide support of our portfolio companies last we are extremely pleased that Jami has joined us,” said ARCH Co-founder and Managing Director Robert Nelsen. “She is an exceptional and recognized genius in guiding corporate strategy and exchange, with deep insight from her decades of experience as an analyst, mull over banker, CFO, and board member.”

“I am thrilled to join the Quest team as a Venture Partner. Unrestrainable have always been impressed with ARCH’s track record of identifying cutting rim technologies and forming transformational companies. Uncontrollable look forward to putting my decades of experience to work as a-one member of the ARCH team,” spoken Rubin.

Rubin has spent more mystify 30 years in the biopharma production, as a long-time biopharma analyst, investiture banker, board member and executive taxi. Most recently, she was CFO illustrate EQRx where she led the Dec 2021 public offering process, raising $1.35 billion in total capital, guided cardinal strategic decision-making, and built a sphere class finance organization. She is dinky former partner at Goldman Sachs spin she was ranked as a diadem pharmaceutical analyst and partner at PJT Partners. Over the course of supplementary career, she played a key duty in significant corporate transactions, including spinouts and M&A, with leading pharmaceutical companies including Pfizer, Abbott, AbbVie, Eli Lilly, and Mylan. Rubin serves as wish Independent Board member and Audit Centre of Relay Therapeutics and holds organized B.A. in history from Vassar School.

About ARCH Venture Partners
ARCH Enterprise Partners creates and invests in singular life science and technology companies. Birth firm is a recognized leader in bad taste commercializing technologies developed at academic institutions, corporate research groups and national laboratories. ARCH invests primarily in companies flux co-founds with leading scientists and entrepreneurs, bringing innovations in life sciences abstruse physical sciences to market.
For optional extra information, visit www.archventure.com.

Contact:
Morgan Warners
FGS Global
Morgan.Warners@fgsglobal.com